Pelthos Therapeutics Inc (PTHS)
Pelthos Therapeutics Inc. is a biotechnology company listed on the NYSE under the ticker PTHS. The company develops and commercializes therapeutic products aimed at addressing conditions with significant unmet treatment needs. Its marketed products include ZELSUVMI, used for molluscum contagiosum in adults and children aged one year and older; XEPI (ozenoxacin) cream, an antimicrobial treatment for impetigo in adult and pediatric patients two months of age and older; and XEGLYZE, a topical treatment for head lice infestation in patients six months of age and older. Pelthos also develops NITRICIL, its proprietary nitric oxide-based technology platform. The company, previously known as Channel Therapeutics Corporation, adopted the Pelthos Therapeutics name in July 2025 and is based in Durham, North Carolina.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-PTHS
|
$22.90
|
34.7% Upside
|
Undervalued
|
$51.71
|
204.2% Upside
|
Bargain
|
Weak
|
0.0%
|
November 12, 2026
|
1.5x
|
65.084 M
|
114 M
|
52.9%
|
35.5%
|
-3.2
|
49.3%
|
